CellEDIT - CRISPR-Engineered PC-3 Cell Line
The PC-3 cell line: Cancer cell model for advanced, androgen-independent prostate cancer
We’ll handle the CRISPR editing of your PC-3 cells, so you can focus on your next discoveries.
PC-3 is a prostate cancer cell line used to model advanced prostate cancer. PC-3 was established in 1979 from a grade IV prostate cancer bone metastases from a 62-year-old Caucasian male. The PC-3 cell line lacks functional androgen receptors and therefore does not respond to first-line androgen treatment and is resistant against conventional chemotherapy and radiation therapies. Because of this, the PC-3 cell line is a commonly used cancer cell line model for androgen-independent prostate cancer. It is known for its highly tumorigenic properties and shows characteristics of highly aggressive prostatic small cell carcinoma making it a valuable tool for studying advanced prostate cancer biology.
PC-3 Cell Line Information
Organism
Homo Sapiens, Human
Tissue Type
Prostate
Cell Type
Epithelial
Disease
Adenocarcinoma
Donor Information
Age
62
Gender
Male
Ethnicity
Caucasian
PC-3 Line Applications
The PC-3 cell line serves as a valuable cell model for studying advanced androgen-independent prostate cancer (AIPC). Because of this, the PC-3 cell line is frequently used in drug discovery research and studies to better understand prostate cancer tumor microenvironment, prostate cancer progression, metastasis and gene expression patterns.
Most prostate cancers are adenocarcinomas that express androgen receptors (AR) and produce prostate-specific antigen (PSA). Unlike typical prostate cancer cell models, PC-3 cells lack expression of both AR and PSA, characteristics associated with a more advanced, aggressive and treatment-resistant state of prostate cancer.
In the progression of prostate cancer, initial treatment often involves androgen deprivation therapy (ADT), as most prostate cancer cells depend on androgens for growth. However, a subset of cancer cells can adapt to lower androgen levels, developing mechanisms to survive and proliferate in an androgen-depleted environment. This progression leads to androgen-independent prostate cancer, which the PC-3 cell line exemplifies.
PC-3 cells, therefore, model the challenging stage of prostate cancer where conventional hormone-based treatments become less effective. They provide researchers with a platform to study the mechanisms of androgen independence and to develop new therapeutic strategies for advanced prostate cancer that have evolved beyond androgen dependence. Recent genomic studies have further characterized the PC-3 cell line, confirming known mutations such as homozygous mutations in TP53 and loss of PTEN. These genetic alterations contribute to the aggressive phenotype of PC-3 cells and their resistance to various therapies.
Other prostate cancer cell lines:
Other prostate cancer cell lines include LNCap, 22RV1 and DU1145, which are sometimes used in combination with PC-3 to study a panel prostate cancer cell model of increasingly aggressive forms of prostate cancer.
Advance your research with CellEDIT’s expertise
Efficient on
Hard-to-transfect cells
Vector-free
direct intra-nuclear delivery
Minimized Off-Target
Immortalized Cells
Learn how the CellEDIT workflow was used to generate 5 monoclonal HPRT knockouts in C2C12 cell line through direct intra-nuclear injection of only 51 cells.
Hard-to-Transfect Cells
Discover how
the CellEDIT workflow was used to produce 3 monoclonal HPRT1 knockouts in SK-MES-1 cell, a notoriously hard-to-transfect cell line.
Available Edits using CellEDIT Engineered Cells
Knockout
Save time in the lab by empowering your research with CellEDIT. Confidently streamline your drug discovery workflow and investigate gene function with effective CRISPR knockouts.
Multiplex Editing
At CellEDIT, we provide you with multiplexed cell lines in 10 weeks. The efficiency and gentleness of our vector-free editing through intra-nuclear delivery, makes it an ideal system to perform multiplex gene editing in one go.
Related Resources
Educational
Technical
Introduction to CRISPR Knockout Gene Editing with CellEDIT
An Overview of CellEDIT' CRISPR Cell Line Development Services
CellEDIT' CRISPR Cell Line Development Workflow
CellEDIT's Engineered Cell Lines
CRISPR-Engineered U2OS Cell Line
CRISPR-Engineered MDA MB 231 Cell Line
CRISPR-Engineered A549 Cell Line
CRISPR-Edited Hek293 Cell Line
CRISPR-Engineered C2C12 Cell Line
Media & Downloads
On-Demand CellEDIT's CRISPR Cell Line Engineering Webinar
CellEDIT's Application Note n*1 - Introducing the CellEDIT Workflow
CellEDIT's Application Note n*2 - Overcoming the hard-to-transfect cell line hurdle
Open Access Publication featuring CellEDIT: Antony, Justin S., Anabel Migenda Herranz, Tahereh Mohammadian Gol, Susanne Mailand, Paul Monnier, Jennifer Rottenberger, Alicia Roig‐Merino et al. " Accelerated generation of gene-engineered monoclonal CHO cell lines using FluidFM nanoinjection and CRISPR/Cas9" Biotechnology Journal 19, no. 4 (2024): 2300505.
Case Study - Streamlined U2OS Cell Line Modification with the CellEDIT Service Workflow, featuring our CellEDIT Customer: Dr. Kanstantsin Siniuk.